THER (Theralink Technologies) GF Value Rank : 0 (As of Sep. 21, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies GF Value Rank?

Theralink Technologies has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Theralink Technologies GF Value Rank Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralink Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401

Website

https://www.theralink.com

Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.

Executives

Danica Holley	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz	director	15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors	director	1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin	director, officer: Chief Executive Officer	HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc	10 percent owner	1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett	officer: Chief Executive Officer	230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb	director	PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman	10 percent owner, officer: Chief Operating Officer-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme	director, 10 percent owner, officer: Global Operations GM-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman	director	C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: CFO & President	549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head	director, officer: Chief Executive Officer	6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817